Status:
NOT_YET_RECRUITING
Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
Lead Sponsor:
Shalamar Institute of Health Sciences
Conditions:
Atopic Dermatitis
Atopic Dermatitis (AD)
Eligibility:
All Genders
2-18 years
Phase:
PHASE3
Brief Summary
This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis. A to...
Eligibility Criteria
Inclusion
- Age 2-18 years Both genders Clinically diagnosed mild to moderate atopic dermatitis Body surface area (BSA) \<30%
Exclusion
- Active viral, bacterial, or fungal skin infection at the treatment site
- Recent use of topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, or immunosuppressive medication within past 2 weeks
- Known hypersensitivity to study medications or components
- Chronic inflammatory conditions (e.g., psoriasis and seborrheic dermatitis) that may interfere with evaluation
Key Trial Info
Start Date :
June 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT07162896
Start Date
June 1 2026
End Date
June 1 2027
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shalamar Hospital Lahore
Lahore, Punjab Province, Pakistan, 54000